8-K: Tarsus Soars on XDEMVY Sales, Targets $2B Peak

Tarsus Pharmaceuticals reported strong full-year 2025 financial results, driven by significant XDEMVY sales growth, and outlined plans for pipeline expansion.

Summary

• Full-year 2025 net product sales of XDEMVY reached $451.4 million, an increase of over 150% year-over-year.
• Fourth quarter 2025 net product sales were $151.7 million, compared to $66.4 million for the same period in 2024.
• Approximately 400,000 bottles of XDEMVY were delivered to patients in full-year 2025, and 130,000 in the fourth quarter.
• The company projects XDEMVY's peak sales potential to exceed $2 billion.
• Net loss for full-year 2025 significantly improved to $66.4 million, down from $115.6 million in 2024.
• A Phase 2 trial of TP-04 for ocular rosacea has been initiated, with topline data expected in 1H 2027.
• Plans are in place to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026.
• David E.I. Pyott, former CEO and Chairman of Allergan, Inc., was appointed to the Board of Directors.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by exceptional sales growth for XDEMVY and promising advancements in a diversified pipeline, indicating strong commercial execution and future growth potential despite ongoing net losses.

Positives

• Full-year 2025 net product sales of XDEMVY increased by over 150% year-over-year to $451.4 million.
• Fourth quarter 2025 net product sales of XDEMVY grew to $151.7 million from $66.4 million in Q4 2024.
• Net loss significantly reduced to $66.4 million for full-year 2025, compared to $115.6 million in 2024.
• Basic and diluted net loss per share improved to $(1.59) for full-year 2025 from $(3.07) in 2024.
• Maintained over 90% commercial, Medicare, and Medicaid covered lives for XDEMVY.
• Direct-to-Consumer (DTC) campaign generated a positive return on investment in 2025, with unaided awareness of Demodex blepharitis increasing from 2% to approximately 25%.
• Initiated Phase 2 trial for TP-04 in ocular rosacea.
• Plans to initiate Phase 2 trial for TP-05 for Lyme disease prevention in Q2 2026.
• Strengthened leadership with the appointment of David E.I. Pyott to the Board of Directors.
• XDEMVY global expansion is on track, with potential approval in Europe (preservative-free formulation) in 2027 and in Greater China in 2026.
• Cash, cash equivalents, and marketable securities stood at $417.3 million as of December 31, 2025.

Negatives

• The company still reported a net loss of $66.4 million for the full year 2025, despite significant improvement.
• Selling, general and administrative (SG&A) expenses increased substantially to $427.3 million for full-year 2025 from $237.3 million in 2024, primarily due to commercial and marketing costs for XDEMVY.
• Research and development (R&D) expenses increased to $64.3 million for full-year 2025 from $53.4 million in 2024.

Risks

• Heavy dependence on the successful commercialization of XDEMVY and the successful development, regulatory approvals, and commercialization of current and future product candidates.
• Ability to obtain and maintain regulatory approval for and successfully commercialize products, including XDEMVY, and product candidates to meet existing and future regulatory standards.
• Incurred significant losses and negative cash flows from operations since inception and anticipates continuing to incur significant expenses and potential losses.
• Capital requirements are difficult to predict and may change, potentially requiring additional funding which, if not obtained on acceptable terms, could force delays or elimination of product development or commercialization efforts.
• May not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis and other diseases targeted by products.
• Development and commercialization of products and product candidates is dependent on intellectual property licensed from Elanco Tiergesundheit AG.
• Expects to expand development, regulatory, operational, sales, marketing, and distribution capabilities and may encounter difficulties in managing growth, which could disrupt operations.
• The sizes of the market opportunity for XDEMVY and product candidates (TP-04 for ocular rosacea, TP-05 for Lyme disease prevention) have not been established with precision and may be smaller than estimated.
• Results of earlier studies and trials may not be predictive of future results.
• Any termination, suspension, or delays in clinical trials could result in increased costs, delay or limit ability to generate revenue, and adversely affect commercial prospects.
• Inability to obtain and maintain sufficient intellectual property protection for XDEMVY or product candidates, or if the scope is not sufficiently broad, could allow competitors to develop similar products.
• Inability to access capital (cash, cash equivalents, credit facilities) and/or loss of capital due to potential failure of financial institutions.

Future Outlook

Tarsus Pharmaceuticals expects XDEMVY to achieve peak sales exceeding $2 billion, driven by continued commercial execution and global expansion efforts, including potential approvals in Europe (preservative-free formulation) in 2027 and Greater China in 2026. The company also plans to advance its pipeline with topline data for TP-04 in ocular rosacea expected in 1H 2027 and the initiation of a Phase 2 trial for TP-05 for Lyme disease prevention in Q2 2026.

Management Comments

• "XDEMVY has driven a fundamental shift in eye care." Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
• "In just two years, we have built broad access, changed how physicians treat, and established a durable and growing franchise, giving us confidence in a clear potential path to peak sales exceeding $2 billion." Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
• "XDEMVY validates our disciplined model for category creation integrating science, commercial execution, and strategic investment." Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
• "We are now applying that proven framework across our pipeline in ocular rosacea and Lyme disease prevention with the goal of establishing additional new standards of care." Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.

Industry Context

StockSavvy.ai notes that Tarsus Pharmaceuticals' strong XDEMVY sales demonstrate successful market penetration and category creation in the specialized eye care segment, particularly for Demodex blepharitis. The expansion into ocular rosacea and Lyme disease prevention with TP-04 and TP-05, respectively, positions Tarsus to diversify its therapeutic portfolio and address other high unmet medical needs, potentially establishing new standards of care in these areas, similar to its success with XDEMVY.

Comparison to Industry Standards

• XDEMVY is highlighted as "one of the best-selling prescription eye drops," indicating strong performance relative to other products in the ophthalmic market.
• The appointment of David E.I. Pyott, former CEO and Chairman of Allergan, Inc., a company he transformed from a $1 billion eye care business into a global specialty pharmaceutical and medical device leader generating over $7 billion in revenue, suggests Tarsus is bringing in leadership with a proven track record of scaling a pharmaceutical company significantly beyond its current size.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, and promising pipeline developments, potentially leading to increased shareholder value.
• Patients: Improved access to XDEMVY for Demodex blepharitis, with ongoing development of new treatments for ocular rosacea and Lyme disease prevention.
• Employees: Continued growth and expansion of the company's commercial and R&D efforts may lead to job stability and potential growth opportunities.
• Physicians/Healthcare Professionals: Increased awareness and adoption of XDEMVY, providing an effective treatment option for Demodex blepharitis.
• Licensor (Elanco Tiergesundheit AG): Continued royalty payments on XDEMVY net product sales.

Next Steps

• Continue global expansion efforts for XDEMVY, including regulatory discussions in Japan.
• Partner Grand Pharmaceutical Group Ltd. expects potential approval of XDEMVY in Greater China in 2026.
• On-track for potential approval of a preservative-free formulation of XDEMVY in Europe in 2027.
• Initiate a Phase 2 study of TP-05 for Lyme disease prevention in Q2 2026.
• Expect topline data from the Phase 2 trial of TP-04 in ocular rosacea in 1H 2027.
• Host a conference call and webcast on February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss results.

Key Dates

Recommendation

The company demonstrated exceptional commercial execution with XDEMVY, achieving over 150% year-over-year sales growth and significantly narrowing its net loss. The projected peak sales potential of over $2 billion for XDEMVY, coupled with a robust pipeline advancing into Phase 2 for ocular rosacea and Lyme disease prevention, indicates strong future growth prospects. The appointment of a highly experienced biopharmaceutical leader to the board further strengthens management. These factors suggest a compelling investment opportunity with significant upside potential.

Keywords

Tarsus Pharmaceuticals, XDEMVY, Demodex blepharitis, ocular rosacea, TP-04, TP-05, Lyme disease prevention, financial results, net product sales, pharmaceutical, biotechnology, eye care, infectious disease, clinical trials, FDA approval, commercialization